Secondary immune-mediated thrombotic thrombocytopenic purpura in idiopathic inflammatory myopathy: a case-based review

被引:0
|
作者
Ruffer, Nikolas [1 ]
Holzer, Marie-Therese [1 ]
Bal, Lukas Can [1 ]
Melderis, Simon [1 ]
Krusche, Martin [1 ]
Huber, Tobias B. [1 ]
Koetter, Ina [1 ,2 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Med 3, Martinistr 52, D-20246 Hamburg, Germany
[2] Klinikum Bad Bramstedt, Dept Rheumatol & Immunol, Bad Bramstedt, Germany
关键词
Antisynthetase syndrome; Myositis; Thrombotic microangiopathy; Thrombocytopenia; ADAMTS13; protein; CONNECTIVE-TISSUE DISEASES; MICROANGIOPATHIES; RITUXIMAB;
D O I
10.1007/s00296-022-05260-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal acquired thrombotic microangiopathy syndrome that frequently develops in the context of infectious diseases or systemic autoimmune conditions including connective tissue diseases. We report the case of a 42-year-old female suffering from severe iTTP associated with anti-Jo-1 positive antisynthetase syndrome, which was successfully treated with combination therapy of intravenous immune globulin, rituximab and plasma exchange. Based on a systematic review of the literature, two additional cases of idiopathic inflammatory myopathy-associated iTTP (secondary iTTP) were identified. In conclusion, iTTP may be a rare complication of IIM that clinicians should consider in cases of marked thrombocytopenia. Further work-up of this finding should include a peripheral blood smear (schistocyte count) and ADAMTS13 activity. The concomitant manifestation of these autoimmune conditions may require intensive immunosuppressive therapy.
引用
收藏
页码:551 / 557
页数:7
相关论文
共 50 条
  • [1] Secondary immune-mediated thrombotic thrombocytopenic purpura in idiopathic inflammatory myopathy: a case-based review
    Nikolas Ruffer
    Marie-Therese Holzer
    Lukas Can Bal
    Simon Melderis
    Martin Krusche
    Tobias B. Huber
    Ina Kötter
    Rheumatology International, 2023, 43 : 551 - 557
  • [4] Congenital and immune-mediated thrombotic thrombocytopenic purpura
    Hovinga, J. A. Kremer
    HAEMOPHILIA, 2018, 24 : 17 - 17
  • [5] Daratumumab for refractory immune-mediated thrombotic thrombocytopenic purpura
    Aggarwal, Asha
    White, Danielle
    Pavord, Sue
    Thomas, Will
    Desborough, Michael J. R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (02) : 429 - 433
  • [6] IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA WITHOUT THROMBOCYTOPENIA
    Ul Abedin, Muhammad Shan
    Batool, Izza
    CHEST, 2024, 166 (04) : 2929A - 2930A
  • [7] Preemptive cyclosporin A in immune-mediated thrombotic thrombocytopenic purpura
    Comparon, Celine
    Galicier, Lionel
    Rebibou, Jean Michel
    Coppo, Paul
    Benhamou, Ygal
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (02) : 157 - 160
  • [8] Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura
    Li, Ang
    Hovinga, Johanna A. Kremer
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 82 - 84
  • [9] Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura
    Poullin, P.
    Bornet, C.
    Veyradier, A.
    Coppo, P.
    DRUGS OF TODAY, 2019, 55 (06) : 367 - 376
  • [10] Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura
    Ozpolat, Hasan Tahsin
    Stolla, Moritz
    BLOOD TRANSFUSION, 2023, 21 (05) : 369 - 374